|Bid||10.80 x 0|
|Ask||10.85 x 0|
|Day's Range||10.69 - 11.25|
|52 Week Range||4.93 - 24.10|
|Beta (5Y Monthly)||3.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 20, 2021 - Sep 24, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.37|
Canadian marijuana stocks have fallen from their February highs. But one player in the industry got a lot bigger after a merger deal.
Canada-based Aurora Cannabis (NASDAQ: ACB) has long been a favorite of investors, having made many of them millionaires in the past after it began selling medical cannabis in the first quarter of 2016 (Canada legalized medical cannabis in 2001). In just the two years between 2016 and 2018, Aurora's share price shot up by 2,400%. The year 2020 was a dreadful one for the company, which repeatedly failed to live up to its promise of achieving positive earnings before interest, tax, depreciation, and amortization (EBITDA).
The first step to making money by investing in stocks is to keep the money you already have. Thankfully, the cannabis industry is maturing, but there are already a few common traits among the weakest performers. Aside from general red flags like indebtedness and unprofitability, be sure to pay attention to these three calling cards for cannabis stocks that'll hurt your portfolio's value.